RSS
Bavarian Nordic
Biotech shows positive results from extension study into universal RSV vaccine
Biotechnology company, Bavarian Nordic, has revealed positive data from the extension study of its Phase II study investigating its universal respiratory syncytial virus (RSV) vaccine, MVA-BN RSV, in older adults. Read more
J&J Ebola vaccine: "Every day counts"
Johnson & Johnson has accelerated its Phase 1, first-in-human clinical trial of a preventive Ebola vaccine, with Chief Scientific Officer Paul Stoffels stating "every day counts". Read more
Bavarian Nordic announces first patient treated in a phase I study of MVA-BN Brachyury in advanced cancer
This immunotherapy is designed to induce a robust immune response against Brachyury, a tumour-associated antigen which is overexpressed in every major solid tumour setting Read more
